Skip to main content
. 2017 Jun 14;8(43):74209–74216. doi: 10.18632/oncotarget.18474

Figure 5. Potential molecular mechanism of the additive effects of the TM6SF2 E167K and PNPLA3 I148M polymorphisms on NAFLD.

Figure 5

The additive effects of the TM6SF2 E167K and PNPLA3 I148M polymorphisms on NAFLD may be associated with upregulating the expression of SREBP-1c and FASN. Abbreviations: SREBP-1c: sterol regulatory element-binding transcription factor 1c; FASN: fatty acid synthase; NAFLD: nonalcoholic fatty liver disease.